News

Article

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Author(s):

Key Takeaways

  • Revumenib is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older.
  • The AUGMENT-101 study showed a 21.2% complete remission rate with a median duration of 6.4 months.
SHOW MORE

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

FDA

FDA

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.1,2

Data from the phase 1/2 AUGMENT-101 study (SNDX-5613-0700; NCT04065399) showed that the menin inhibitor (n = 104) led to a complete remission (CR) plus CR with partial hematologic recovery (CRh; CR+CRh) rate of 21.2% (95% CI, 13.8%-30.3%) with a median duration of CR+CRh of 6.4 months (95% CI, 2.7-not estimable [NE]). In the patients who achieved a CR or CRh with revumenib (n = 22), the median time to response was 1.9 months (range, 0.9-5.6).

Moreover, 14% of 83 patients who were dependent on red blood cell (RBC) and platelet transfusions at baseline achieved independence during any 56-day post-baseline period, and 48% of 21 patients who were independent at baseline remained independent.

"The FDA approval of the first menin inhibitor is a major breakthrough for patients with R/R acute leukemia with a KMT2A translocation, a genetic alteration associated with a very poor prognosis," Ghayas C. Issa, MD, associate professor of leukemia at The University of Texas MD Anderson Cancer Center, stated in a news release.3 "The significant clinical benefit and robust efficacy seen with Revuforj represents a substantial improvement over what has been historically observed in these patients with previously available therapies and has the potential to be an important new treatment option for patients."

In a past interview with OncLive, Dan Pollyea, MD, MS, clinical director of Leukemia Services; Robert H. Allen Endowed Chair in Hematology Research; and associate professor of medicine in the Division of Hematology at the University of Colorado School of Medicine, discussed the mechanism of action for revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML):

About AUGMENT-101: Eligibility, Treatment, Objectives

The single-arm cohort of an open-label, multicenter trial enrolled adult and pediatric patients at least 30 days old who had relapsed or refractory acute leukemia harboring a KMT2A translocation.2 To be eligible, patients needed to have a corrected QT interval of less than 450 milliseconds. Those with an 11q23 partial tandem duplication were not permitted.

Revumenib was administered at a dose that was approximately equivalent to 160 mg in adults orally twice daily with a strong CYP3A4 inhibitor. Treatment continued until progressive disease, intolerable toxicity, failure to achieve a morphological leukemia-free state by 4 cycles of treatment, or hematopoietic stem cell transplantation.

The primary end point was CR+CRh rate.

Diving Into Demographic and Disease Characteristics

In the cohort (n = 114) median patient age was 37 years (range, 1-79), with 24% younger than 17 years. More than half of the patients (64%) were female and most were White (72%) and not Hispanic or Latino (73%). Eighty-three percent of patients had AML, 15% had acute lymphoblastic leukemia, and 2% had mixed phenotype acute leukemia.

Moreover, 22%, 19%, 10%, 10%, 7%, 3%, 2%, 2%, and 1% of patients had t(9;11), t(11;19), t(6;11), t(10;11), t(4;11), t(1;11), t(11;17), t(11;22), and t(11;16), respectively. Twenty-five percent of patients had an unknown KMT2A fusion partner. More than half of patients had relapsed/refractory disease (59%); 21% and 20% of patients had primary refractory or untreated relapsed disease.

The median number of previous regimens received was 2, with a range of 1 to 11 regimens. Forty-four percent of patients underwent prior stem cell transplantation. Fifty-three percent of patients had 1 prior relapse, 19% had 2 prior relapses, and 7% had 3 or more prior relapses.

Additional Efficacy Data

The median follow-up was 5.73 months (range, 0.3-28.9). Additional findings showed that 12.5% (95% CI, 6.8%-20.4%) of patients achieved a CR and the median duration of CR was 4.3 months (95% CI, 1.0-NE). The CRh rate was 8.7% (95% CI, 4.0%-15.8%) and the median duration of CRh was 6.4 months (95% CI, 1.9-NE).

Subgroup analysis revealed that CR+CRh was achieved in 21%, 19%, and 50% of patients with AML (n = 18/86), ALL (n = 3/16), and MPAL (n = 1/2), respectively.

Shedding Light on Safety

The safety of revumenib was examined in 104 adult patients and 31 pediatric patients with relapsed or refractory acute leukemia and a KMT2A translocation. The median duration of exposure was 2.3 months (range, <1-23).

The most common toxicities experienced by at least 20% of patients included hemorrhage (all grade, 53%; grade 3/4, 9%), nausea (51%; 4%), musculoskeletal pain (42%; 6%), infection (41%; 29%), febrile neutropenia (35%; 33%), bacterial infection (31%; 20%), diarrhea (30%; 4%), differentiation syndrome (29%; 13%), prolonged electrocardiogram QT (29%; 12%), decreased appetite (24%; 8%), constipation (23%; 1%) viral infection (23%; 4%), edema (23%; 1%), fatigue (22%; 5%), thrombosis (10%; 5%), and leukocytosis (8%; 5%).

Forty-two percent of patients experienced adverse effects (AEs) that required dose interruptions and 10% experienced AEs that led to dose reductions. Serious AEs were reported in 73% of patients and 3% experienced AEs that proved fatal (differentiation syndrome, n = 2; hemorrhage, n = 1); sudden death, n = 1).

References

  1. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. FDA. November 15, 2024. Accessed November 15, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation
  2. Revuforj. Prescribing information. Syndax Pharmaceuticals, Inc.; 2024. Accessed November 15, 2024. https://cms.syndax.com/wp-content/uploads/Revuforj-full-prescribing-info.pdf
  3. Syndax announces FDA approval of Revuforj (revumenib), the first and only menin inhibitor to treat adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A translocation. News release. Syndax Pharmaceuticals, Inc. November 15. 2024. Accessed November 15, 2024. https://ir.syndax.com/news-releases/news-release-details/syndax-announces-fda-approval-revuforjr-revumenib-first-and-only
Related Videos
Cedric Pobel, MD
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.